Who is WHO and what was REAL?

A review of the new WHO classification (2001) for malignant lymphomas

Sergio B. Cogliatti, Ulrico Schmid

Department of Pathology, Cantonal Hospital St. Gallen, Switzerland

Summary

The principles of the new WHO classification of haematopoietic and lymphoid tumours are based on those defined in the Revised European American classification of Lymphoid neoplasms (REAL), published by the International Lymphoma Study Group (ILSG) in 1994. Thus, the new WHO classification may be considered an updated version of the REAL classification rather than of the old WHO classification published in 1976. Disease entities are defined on the basis of morphological, phenotypic, genotypic, and clinical data. The relative impact of these characteristics varies among different diseases and there is "no gold standard". Thus, the strict hierarchy among diagnostic criteria, headed by morphology and followed by immunohistochemistry and genetics, has been discontinued. The WHO classification not only encompasses lymphoid tumours but extends to myeloid, mast cell and histiocytic/dendritic cell malignancies. Neoplasms are primarily stratified according to their tumour cell lineage. For each neoplasm a cell of origin is postulated. The classification of lymphoid malignancies recognises three major categories, B-cell neoplasms, T-/NK-cell neoplasms, and Hodgkin lymphomas. B-cell and T-cell lymphomas are further divided into precursor neoplasms and mature neoplasms, the latter being subdivided according to their clinical manifestation into disseminated/leukaemic, extranodal and nodal malignancies. In contrast to previous classifications, the neoplasms are grouped neither according to their histological grade (Kiel classification) nor according to their clinical aggressiveness (International Working Formulation). However, the histological grade is considered a prognostic factor which enters into the description of each disease entity. Hodgkin's disease, now more appropriately termed Hodgkin lymphoma, comprises nodular lymphocyte-predominant Hodgkin lymphoma and classical Hodgkin lymphomas of nodular sclerosis, mixed cellularity, lymphocyte-depleted and lymphocyte-rich subtype.

For practical purposes this minireview disregards the description of myeloid, macrophage/histiocytic, dendritic cell and mast cell disorders. Furthermore, the present paper is restricted to those lymphoid tumours that are not already identically described in the REAL classification, in order to focus on what is really new in the WHO classification.

Key words: lymphoma classification; WHO; REAL; Kiel; non-Hodgkin lymphoma; Hodgkin lymphoma
Table 1

Entities of the WHO classification for lymphoid neoplasms (2001) and their equivalents in the updated Kiel classification (1992) and the REAL classification (1994). Provisional entities of the REAL classification are printed in italics. Major differences between the WHO and the REAL classification, as described in the text, are underlined with colour. By accident, diffuse large B-cell lymphoma and intravascular large B-cell lymphoma are given the same code-number (9680/3) in the original literature [8]. This mistake has been reported to one of the editors of the WHO book.

<table>
<thead>
<tr>
<th>Kiel (updated) 1992</th>
<th>REAL 1994</th>
<th>WHO 2001</th>
<th>ICD-O code</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>B-cell lymphomas</strong></td>
<td><strong>B-cell neoplasms</strong></td>
<td><strong>B-cell neoplasms</strong></td>
<td><strong>ICD-O code</strong></td>
</tr>
<tr>
<td>Acute lymphoblastic B-cell leukaemia</td>
<td>Precursor B-cell neoplasm</td>
<td>Precursor B-cell neoplasm</td>
<td>9835 / 3</td>
</tr>
<tr>
<td>B lymphoblastic lymphoma</td>
<td>B lymphoblastic leukaemia / lymphoma</td>
<td>B lymphoblastic leukaemia / lymphoma</td>
<td>9728 / 3</td>
</tr>
<tr>
<td><strong>Peripheral B-cell neoplasms</strong></td>
<td><strong>Mature B-cell neoplasms</strong></td>
<td><strong>ICD-O code</strong></td>
<td></td>
</tr>
<tr>
<td>B-cell chronic lymphocytic leukaemia</td>
<td>B-cell chronic lymphocytic leukaemia / small lymphocytic lymphoma</td>
<td>Chronic lymphocytic leukaemia / small lymphocytic lymphoma</td>
<td>9823 / 3</td>
</tr>
<tr>
<td>Immunocytoma, lymphoplasmacytoid type</td>
<td>B-cell prolymphocytic leukaemia</td>
<td>B-cell prolymphocytic leukaemia</td>
<td>9833 / 3</td>
</tr>
<tr>
<td>Immunocytoma, lymphoplasmacytic type</td>
<td>Lymphoplasmacytoid lymphoma / immunocytoma</td>
<td>Lymphoplasmacytoid lymphoma</td>
<td>9671 / 3</td>
</tr>
<tr>
<td>Splenic marginal zone lymphoma (± villous lymphocytes)</td>
<td>Nodal marginal zone B-cell lymphoma (± villous lymphocytes)</td>
<td>Nodal marginal zone B-cell lymphoma (± villous lymphocytes)</td>
<td>9699 / 3</td>
</tr>
<tr>
<td>Hairy cell leukaemia</td>
<td>Hairy cell leukaemia</td>
<td>Hairy cell leukaemia</td>
<td>9940 / 3</td>
</tr>
<tr>
<td>Plasmacytic lymphoma (Plasmacytoma)</td>
<td>Plasmacytoma / Plasma cell myeloma</td>
<td>Plasma cell neoplasms</td>
<td>9678 / 3</td>
</tr>
<tr>
<td>Marginal zone B-cell lymphoma, extranodal (MALT-type ± monocytoid B cells)</td>
<td>Extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue (MALT lymphoma)</td>
<td>Extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue (MALT lymphoma)</td>
<td>9699 / 3</td>
</tr>
<tr>
<td>Monocytoid B-cell lymphoma</td>
<td>Marginal zone B-cell lymphoma, nodal (± monocytoid B cells)</td>
<td>Nodal marginal zone B-cell lymphoma (± monocytoid cells)</td>
<td>9699 / 3</td>
</tr>
<tr>
<td><strong>Centroblastic-centrocytic lymphoma,</strong> follicular, follicular and diffuse – with an increased number of centroblasts</td>
<td><strong>Centroblastic-centrocytic lymphoma,</strong> follicular, follicular and diffuse – with an increased number of centroblasts</td>
<td><strong>Centroblastic-centrocytic lymphoma,</strong> follicular, follicular and diffuse – with an increased number of centroblasts</td>
<td>9670 / 3</td>
</tr>
<tr>
<td>Grade I</td>
<td>Grade II</td>
<td>Grade III</td>
<td>Grade III</td>
</tr>
<tr>
<td>Centroblastic lymphoma, follicular</td>
<td>Centroblastic lymphoma, follicular</td>
<td>Centroblastic lymphoma, follicular</td>
<td>9671 / 3</td>
</tr>
<tr>
<td>Centroblastic-centrocytic lymphoma, diffuse</td>
<td>Follicle centre lymphoma, diffuse, small cell</td>
<td>Follicle centre lymphoma, diffuse, small cell</td>
<td>9672 / 3</td>
</tr>
<tr>
<td>Centrocytic (mantle cell) lymphoma</td>
<td>Mantle cell lymphoma</td>
<td>Mantle cell lymphoma</td>
<td>9673 / 3</td>
</tr>
<tr>
<td>Centroblastic lymphoma, centrocytoid</td>
<td>Diffuse large B-cell lymphoma</td>
<td>Diffuse large B-cell lymphoma</td>
<td>9680 / 3</td>
</tr>
<tr>
<td><strong>Angio-endotheliomatous (intravascular) lymphoma</strong></td>
<td><strong>DLBCL subtype:</strong> Primary mediastinal (thymic) lymphoma</td>
<td><strong>Mediastinal (thymic) large B-cell lymphoma</strong></td>
<td>9679 / 3</td>
</tr>
<tr>
<td>Burkitt lymphoma (BL)</td>
<td>Burkitt's lymphoma</td>
<td>Burkitt lymphoma</td>
<td>9687 / 3</td>
</tr>
<tr>
<td>BL with intracytoplasmic immunoglobulin</td>
<td><strong>DLBCL subtype:</strong> High-grade B-cell lymphoma, Burkitt-like</td>
<td>BL with plasmacytoid differentiation atypical BL / Burkitt-like</td>
<td>9826 / 3</td>
</tr>
<tr>
<td>Lymphomatoid granulomatosis (Liebow)</td>
<td>Lymphomatoid granulomatosis</td>
<td>Lymphomatoid granulomatosis</td>
<td>9766 / 1</td>
</tr>
<tr>
<td><strong>Post-transplant lymphoproliferative disorder, polymorphic</strong></td>
<td>9970 / 1</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
Introduction

Classification of diseases is one of the most straightforward analytical endeavours in traditional medicine which mirrors temporary knowledge on a specific subject. In the field of malignant lymphomas an iterative renewal of classification seems to be inevitable, having regard to the continuous accumulation of new insight into their biology. Thus, proposals for new classifications should be understood as a compulsory step-by-step update process reflected in a constant adaptation of nomenclature, inasmuch as more appropriate terms which better contribute to newly discovered characteristics replace old names which have lost their meaning.

Modern technologies yield new criteria which fuel new concepts to interpret old entities. Thus,
The new WHO classification (2001) for malignant lymphomas

The new WHO classification (2001) for malignant lymphomas has introduced a system that subdivides tumors into easily distinguishable groups, which has replaced pre-existing classifications based on pathological, phenotypic, genotypic, and clinical characteristics. This classification reflects the concept of histogenetically defined tumor cells and their physiological counterparts respectively. With prognostic tumor grouping according to the aggressiveness of diseases into low, intermediate, and high grade malignancies, a clinical approach was adopted in the International Working Formulation (IWF) which was actually meant to serve as a translational tool between pre-existing classifications rather than as a classification of its own. Finally, a synthesis of morphological, phenotypic, genotypic, and clinical characteristics is mandatory for the diagnosis of disease entities, morphological variants and clinical subtypes as defined in the REAL [6, 7] and WHO [8] classifications.

Thus, the 2001 WHO classification of lymphoid tumors (table 1) is the latest, but definitely not the last attempt at a consensus among clinicians and pathologists on the definition of “real” entities and their diagnostic criteria. However, since it is based on agreement between 51 experts worldwide, the WHO classification conveys the best international acceptance ever achieved. It fulfills the requirements of a modern classification, since it is conceptually and scientifically accurate, flexible and easily modified, understandable in its nomenclature and clinically useful for therapeutic trials. However, the diagnostic process, involving as it does today an increasingly complex multivariate genetically biased approach, is no longer practicable in every kind of non-universal laboratory, since it requires facilities far exceeding the simple repertoire of daily tools at hand.

B-cell neoplasms

Chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL), B-cell prolymphocytic leukemia (B-PLL) and lymphoplasmacytic lymphoma (LPL) (table 2)

The WHO classification separates B-cell prolymphocytic leukemia from chronic lymphocytic leukemia/small lymphocytic lymphoma and, as in the Kiel classification, defines it as a disease entity of its own. Lymphoplasmacytic lymphoma (LPL), which was named lymphoplasmacytoid lymphoma (immunocytoma) in the REAL classification and corresponds to the Kiel classification’s immunocytoma, lymphoplasmacytoid type, shows a considerable overlap with marginal zone B-cell lymphoma. As in the REAL classification, LPL is distinguished from lymphocytic lymphomas with or without plasmacytoid differentiation.

Extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue (MALT lymphoma), nodal marginal zone B-cell lymphoma (± monocytoid cells), and splenic marginal zone lymphoma (± villous lymphocytes) (table 3)

For these three types of lymphoma, for which the term marginal zone is used, the WHO classification is conceptually identical with the REAL classification, with the sole difference that nodal marginal zone B-cell lymphoma and splenic marginal zone lymphoma are no longer provisional entities. Thus, extranodal marginal zone B-cell lymphomas (MALT lymphomas) and nodal marginal zone B-cell lymphomas are very closely related tumors, both recognized as being derived from post-germinatal marginal zone B cells (memory B cells). However, splenic marginal zone lymphoma (SMZL) with or without villous lymphocytes differs markedly in its clinical manifestation, morphological presentation and phenotypic and genotypic profile, originating from a post-germinatal center B cell of unknown differentiation state [9–12].

Follicular lymphoma

The histogenetically coined term follicle centre lymphoma, follicular as proposed in the REAL classification and preceded by centroblastic-centrocytic lymphoma in the original Kiel classification, has been replaced by the pattern-descriptive term follicular lymphoma (FL). The growth pattern of these tumors is usually follicular (follicularity >75%) and less often follicular and diffuse (follicularity 25–75%) or minimally follicular (follicularity <25%). While semantically the WHO classification emphasizes follicularity as the hallmark feature, it also recognizes more variable characteristics such as interfollicular tumour components, marginal zone differentiation, plasmacytoid differentiation with signet ring cells, or focial germinal centres as previously described by others [13–16].

A provisional histological grading system without specific criteria, as used in the REAL classification, has been standardised in the WHO classification on the strength of Berard’s criteria [17]. On the basis of counts of centroblasts (CB) in 10 neoplastic follicles in 40× high power field magnification (hpf), FL are subgrouped into Grade 1 (0–5 CB/hpf), Grade 2 (6–15 CB/hpf), and Grade 3 (>15 CB/hpf) tumors. Among Grade 3 FL, the
WHO classification additionally distinguishes those with solid sheets of centroblasts (grade 3b) from those in which centroblasts are intermingled with centrocytes (grade 3a). Small areas of grade 3 FL in otherwise grade 1 or grade 2 FL are diagnosed separately, with an approximate quantification of both tumour components. Likewise, two separate diagnoses are given in cases of FL with considerable diffuse centroblastic areas, namely follicular lymphoma and diffuse large B-cell lymphoma.

Diffuse large B-cell lymphoma, mediastinal (thymic) large B-cell lymphoma, intravascular large B-cell lymphoma, primary effusion lymphoma, and Burkitt lymphoma

Diffuse large B-cell lymphoma (DLBCL), as a term, was coined by the ILSG in proposing the REAL classification. Thus, clinicopathological entities such as diffuse centroblastic lymphoma of polymorphic, monomorphic and multilobated subtype, immunoblastic lymphoma, and B-cell anaplastic lymphoma, as previously defined in the Kiel classification, were lumped together in the DLBCL category. The authors believed that, in view of inadequate knowledge of the biology of these tumours, a purely morphological subclassification with no specific phenotypic and/or genotypic background was useless and not sufficiently reproducible. Some cases with morphological features intermediate between DLBCL, centroblastic variant and Burkitt's lymphoma, expression of bcl-2 protein and bcl-2 rearrangement in some
30% but no c-myc rearrangement, corresponding in part to Burkitt lymphomas with intracytoplasmic immunoglobulin as defined in the Kiel classification, were provisionally subtyped as high-grade B-cell lymphoma, Burkitt-like. Additionally, primary mediastinal (thymic) large B-cell lymphoma was classified as a clinically distinctive subtype of DLBCL.

DLBCL in terms of the WHO classification encompasses a group of cytologically heterogeneous tumours composed of large transformed lymphoid cells. Morphologically they are subdivided into centroblastic, immunoblastic, T-cell/histiocyte rich and anaplastic variants of DLBCL. However, distinction of these variants has met with poor intra- and interobserver reproducibility, inter alia because, with rare exceptions, phenotypic and genotypic features do not reveal discriminating profiles. Thus, it is optional for the pathologist to give the diagnosis of a DLBCL or more specifically of a morphological variant. In the WHO classification the category of DLBCL comprises, as a new feature, two other variants with distinctive phenotypes. The plasmablastic variant as usually present in the oral cavity in an HIV+ setting is positive for EBV and plasma cell antigens, but negative for CD45 and CD20. The variant with expression of full-length ALK, as described by Delsol [20], has an immunoblastic morphology with mainly plasmablastic differentiation and expresses EMA, CD45, IgA, ALK and plasma cell antigens but no B- and T-cell antigens except CD4 and CD57. Unlike anaplastic large cell lymphoma, it has no t(2;5) translocation, no NPM-ALK hybrid gene, and no NPM-ALK fusion transcript (see below).

Clinically, DLBCL follow an aggressive course but respond very variously to treatment in that only some 40% can be cured. Looking for prognostically discriminating features Aliasadeh et al. [21] followed a genetic approach. They functionally classified many hundreds of genes by means of DNA microarrays and established an outcome predictor score. Thus, on the basis of different gene expression signatures suggestive of different stages of B-cell differentiation, two major subtypes with significantly different clinical outcomes were distinguished, namely the prognostically favourable Germinal Centre B-cell-like (GCB) DLBCL and the unfavourable Activated B-Cell-like (ABC) DLBCL. Clinically distinctive subtypes such as mediastinal (thymic), intravascular and primary effusion large B-cell lymphomas are excluded from the DLBCL category and recognised as separate disease entities.

Mediastinal (thymic) large B-cell lymphoma (MLBCL) was also recognised and well described in the REAL classification. It originates from pu-

### Table 3

<table>
<thead>
<tr>
<th>Diagnostic criteria</th>
<th>Extranodal marginal zone B-cell lymphoma (MALT)</th>
<th>Nodal marginal zone B-cell lymphoma</th>
<th>Splenic marginal zone lymphoma (SMZL)</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Clinics</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Presentation</td>
<td>stomach lungs head and neck</td>
<td>localized/generalized lymphadenopathy, spleen and bilar lymph nodes, in 1/3 of the cases in combination with a MALT lymphoma, no generalized lymphadenopathy</td>
<td></td>
</tr>
<tr>
<td></td>
<td>ocular adnexae skin, thyroid breast, parotid gland ...</td>
<td>in 1/3 of the cases in combination with a MALT lymphoma</td>
<td></td>
</tr>
<tr>
<td></td>
<td>tissue-specific homing pattern</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Stage</td>
<td>I and IIE &gt; IIE and IVE</td>
<td>I, II, III, IV</td>
<td>IIE and IVE &gt; IIE and IIE</td>
</tr>
<tr>
<td>– Bone marrow</td>
<td>+</td>
<td>++</td>
<td>+++</td>
</tr>
<tr>
<td>– Leukaemic</td>
<td>(+)</td>
<td>(+)</td>
<td>+++ villous lymphocytes</td>
</tr>
<tr>
<td><strong>Morphology</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Tumour cells</td>
<td>marginal zone (centrocyte-like) B-cells, monocytoid B-cells and/or small B-lymphocytes with plasma cell differentiation and intermingled blasts of immunoblast/centroblast type</td>
<td>biphasic: central small lymphocytes in the mantle zone and peripheral marginal zone cells in the marginal zone</td>
<td></td>
</tr>
<tr>
<td>Special features</td>
<td>lymphoepithelial lesions</td>
<td>monocytoid B-cells</td>
<td>bone marrow: intrasinusoidal</td>
</tr>
<tr>
<td></td>
<td>active residual lymph follicles</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>high grade transformation / progression into diffuse large B-cell lymphoma (DLBCL)</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

### Phenotype

| positive                           | CD20⁺ CD79a⁺ | IgM⁺ CD43⁻ bcl-10⁻ | IgM⁺ IgD⁻⁺ DBA44⁻⁺ CD103⁻ |
| negative                           | CD5⁺ CD10⁺ CD23⁻ IgD⁻ | CD5⁺ CD10⁺ CD23⁻ CD43⁻ | CD5⁺ CD10⁺ CD23⁻ CD43⁻ |

### Genotype

<table>
<thead>
<tr>
<th>V_{H} translocations and chromosomal aberrations</th>
</tr>
</thead>
<tbody>
<tr>
<td>t(1;14) (p22;q32) → nuclear bcl-10 expression</td>
</tr>
<tr>
<td>t(11;18) (q21;q21) API2–MLT fusion transcript</td>
</tr>
</tbody>
</table>
tative thymic B-cells (asteroid cells) or post-germinal centre cells of very late pre-plasmacyte B-cell differentiation. Phenotypically it can be distinguished from Hodgkin lymphoma by the expression of CD45, Bob-1 and Oct-2, MAL and CD23 and the absence of immunoreactivity for CD15. Specific genotypic aberrations in MLBL comprise REL gene amplification, gains of chromosome 9, MAL gene overexpression and bcl-6 mutations [22].

Intravascular large B-cell lymphoma is a very rare type of B-cell lymphoma originating from transformed peripheral B-cells and presenting as an intravascular accumulation of B-blasts (CD20+). It is widely disseminated at extranodal sites and the clinical symptoms are related to occlusions of small vessels in the relevant organ. The response to therapy is very poor and the prognosis is extremely unfavourable [23].

Primary effusion lymphoma originates from post-germinal centre B-cells and manifests itself as serous effusions in body cavities, usually in an HIV+ setting associated with HHV8/KSHV infections, with or without Kaposis's sarcoma or multicentric Castleman's disease. The prognosis is extremely unfavourable. The tumour cells of centroblastic, immunoblastic, or anaplastic morphology express CD45, plasma cell markers and HHV8/KSHV-associated latent protein but no pan-B-cell antigens and no immunoglobulins [24].

Burkitt lymphoma (BL) is a highly aggressive tumour most typically of extranodal origin which in very rare cases presents as acute leukemia. In spite of its unfavourable natural history it is highly sensitive to aggressive chemotherapy and is thus in fact curable in most cases. Epidemiologically the WHO classification distinguishes three clinical variants, viz. endemic BL of equatorial Africa and Papua New Guinea, sporadic BL with worldwide occurrence, and the immunodeficiency-associated BL usually found in an HIV+ setting. These variants are markedly heterogeneous in their biology, i.e. the pathogenetic impact of Epstein-Barr virus (EBV) infections, clinical presentation, i.e. site of origin, and morphological subtypes such as classi-

fied BL representing endemic and sporadic variants and BL with plasmacytoid differentiation and atypical BL/Burkitt-like subtypes, both found chiefly in combination with HIV infection. Compared to classical BL, variants with plasmacytoid differentiation and atypical BL/Burkitt-like show more morphological atypias and considerable pleomorphism of nuclear shape and size. They may correspond in part to the provisional entity of high-grade B-cell lymphoma, Burkitt-like as defined in the REAL classification. Phenotypically, BL express B-cell antigens, CD10, and bcl-6 protein and are negative for CD5, CD23 and TdT. The proliferation index as measured by nuclear immunoreactivity with Mib-1 (Ki67) is higher than 95%. Monotypic cytoplasmic Ig is found in BL with plasmacytoid differentiation. Burkitt leukaemias exhibit a mature B-cell phenotype positive for CD45 and B-cell antigens and negative for CD34 and TdT. On the basis of morphological and immunological criteria alone, differential diagnosis between BL and DLBCL leaves a considerable grey zone open. Thus clinical data, such as extrana
dodal tumour bulk, high serum LDH and tumour lysis syndrome are very valuable diagnostic parameters. In the WHO classification, however, c-myc rearrangements, due to t(8;14) rather than to t(2;8) or t(8;22) translocation is an invariable genetic feature of BL. Originating from germinal centre B-cells, BL shows ongoing somatic hypermutations of the Ig-VH genes.

Lymphomatoid granulomatosis and post-transplant lymphoproliferative disorder

In addition to B-cell neoplasms the WHO classification encompasses two types of B-cell proliferation of uncertain malignant potential, which are not contained in the REAL classification. Lymphomatoid granulomatosis, as previously described by Liebow [25], is an EBV-driven lymphoproliferative disorder chiefly found in patients with underlying immunodeficiency caused by HIV infection, Wiscott-Aldrich's syndrome or the X-linked lymphoproliferative syndrome. It is localised in extranodal organs, most typically in the lungs, and the clinical symptoms are, apart from constitutional symptoms, related to the relevant organ infiltration. It shows an angiocentric and angiodestructive growth pattern with infarctious lesions and is to be distinguished from extranodal NK-/T-cell lymphoma, nasal type (see below). Morphologically the infiltrate is composed of EBV-positive atypical blasts of B-cell phenotype (CD20+) admixed with numerically predominant reactive T-lymphocytes, plasma cells and histiocytes. Depending on the varying proportions of these large B cells and the extent of necrosis, lymphomatoid granulomatosis varies in histological grade (I–III) and clinical aggressiveness. While most cases of grade II and grade III disease exhibit clonally rearranged immunoglobulin genes, grade III cases display the morphology of overt B-cell lymphoma, which the WHO classification considers a subtype of DLBCL.

Post-transplant lymphoproliferative disorder (PTLD) encompasses a continuous spectrum of largely EBV-infection-associated lymphoid proliferations, mainly of host rather than of donor origin and consequently evolving to immunosuppression in recipients of allografts. PTLD are divided into early lesions, polymorphic PTLD, monomorphic PTLD and Hodgkin lymphoma, including Hodgkin-like PTLD. Early lesions, i.e. reactive plasmacytic hyperplasia and infectious mononucleosis-like lesions, are characterised morphologically by at least partial architectural preservation of infiltrated tissues, phenotypically by polyclonal Ig expression and LMP-EBV positivity, and genotypically by a germline Ig configuration. Clinically, they show spontaneous regression with reduction of immunosuppression in most
cases. Polymorphic PTLD present morphologically
as a tissue-destructive B- and T-cell mixed lymphoproliferation with intermingled atypical, bizarre EBV-positive immunoblasts showing the full range of B-cell maturation to plasma cells, thus resembling the composition of "polymorphic immunocytoma" as described in the original Kiel classification. Phenotypically they express monotypic Ig. Genotypically they nearly always have clonally rearranged Ig genes and EBV genomes. Clinically they may regress but usually progress to monomorphic PTLD. Monomorphic PTLD corresponds morphologically, phenotypically and genotypically to overt lymphoma of B-cell subtype rather than of T-cell subtype with clonal Ig profiles and EBV genomes in clonal episomal forms. Some PTLD present as Hodgkin lymphoma or Hodgkin-like lesions, similar to methotrexate-related HL or HL in an HIV+ setting.

---

**T-cell and NK-cell neoplasms**

**Blastic NK-cell lymphoma**

Blastic NK-cell lymphoma is a new entity to the WHO classification not recognised by the REAL classification. It is a clinically aggressive lymphoma with a poor response to treatment protocols, no known racial predilection and no association with EBV infection. Usually a disseminated disease at presentation, it shows infiltration of multiple extranodal sites, preferably the skin, and at least partly represents precursor NK lymphoblastic lymphoma/leukaemia. Because of a phenotypic overlap with other primary cutaneous haematolymphoid neoplasms and a morphological resemblance to lymphoblastic (or myeloblastic) leukaemias, adequate phenotypic (CD56+ CD4+ CD43+ TdT–/− CD34/s+ CD123+ CD3– CD7– TIA-1− CD68– CD33+) and genotypic (germline configuration of T-cell receptor genes) profiles are mandatory [26, 27].

**T-cell prolymphocytic leukaemia**

In the WHO classification T-cell prolymphocytic leukaemia (T-PLL) replaces, as a term, the REAL classification's hybrid entity T-cell chronic lymphocytic leukaemia/prolymphocytic leukaemia. T-PLL represents a morphological spectrum of clonal diseases of T-prolymphocytes (and T-lymphocytes), including a small cell variant (20%) and a cerebriform or Sézary cell-like variant (5%) [28, 29]. These variants of T-PLL may in part correspond to some cases of T-cell chronic lymphocytic leukaemia (T-CLL) of knobby type (and of pleomorphic type respectively) as defined in older classifications [2–4], whereas the azurophilic type of T-CLL is covered by T-cell large granular lymphocytic leukaemia [30]. In terms of the Kiel classification, T-PLL and T-CLL can be distinguished only on imprints and peripheral blood smears, but not on histological sections [3]. Immunologically, T-PLL exhibits a profile of mature T-cells with constant expression of CD7, characteristically variable CD4/CD8 status, and constant negativity for HTLV-1. Clinically, T-PLL presents with hepatosplenomegaly, generalised lymphadenopathy, skin infiltration in 20%, and marked lymphocytosis exceeding 100×10⁹/L. It follows an aggressive course showing an encouraging response in cases treated with CD52 monoclonal antibodies (CAMPATH-1H). Terminologically, however, T-CLL no longer figures in the WHO classification.

**Extranodal NK-/T-cell lymphoma, nasal type**

Renamed according to the new nomenclature, extranodal NK-/T-cell lymphoma, nasal type is not an entity new to the WHO classification but is equivalent to the angiocentric (T-cell) lymphoma well defined in the REAL classification. Angiocentricity, angioinvasion, and angiodestruction are histomorphological hallmarks of this cytologically variegated tumour, resulting in vascular occlusions and consequent ischaemic necrosis and ulceration. Involvement of the nasal cavity, being the prototypic extranodal site of origin, may present as mid-facial destruction also known by the descriptive term lethal midline granuloma. Lymphomatoid granulomatosis, however, may be distinguished immunologically and represents a lymphoproliferative disorder of B-cell lineage. Phenotypically, extranodal NK-/T-cell lymphoma, nasal type most typically exhibits CD2, CD56, EBV, cytotoxic antigens and cytoplastic CD3, but no surface CD3 and no CD4, CD5, CD8, or CD43. Genotypically, Ig and TcR genes are found to be in germline configuration, whereas EBV genomes present in clonal episomal forms.

**Hepatosplenic T-cell lymphoma and subcutaneous panniculitis-like T-cell lymphoma**

These two disease entities, both associated with an immunosuppressive setting, were, under the terms hepatosplenic γδ T-cell lymphoma and subcutaneous panniculitic T-cell lymphoma respectively, also recognised by the REAL classification, categorised then as provisional subtypes of peripheral T-cell lymphomas, unspecified. The first originates from immature, the latter from mature cytotoxic T-cells, of both γδ- and αβ-types. This is why the “gd”-affix in hepatosplenic T-cell lymphoma is deleted in the WHO classification nomenclature.
Anaplastic large cell lymphoma, primary cutaneous anaplastic large cell lymphoma (C-ALCL), and lymphomatoid papulosis

Anaplastic large cell lymphoma is the prototype of a lymphoid neoplasm which has been named and renamed according to changing interpretations, initially on the basis of morphological and phenotypic and later of genotypic features and yet may still not be ultimately defined! In 1985, when Stein et al. incubated a series of morphologically unclassifiable tumours with the Hodgkin's disease-associated antibody Ki-1 (CD30), it was found that there was a new Ki-1 positive large cell lymphoid neoplasm which had not been recognised before [31]. On the basis of cytologically large- to giant-sized tumour cells, which could not then be correlated with any known physiological or neoplastic lymphoid cells, the morphological term large cell anaplastic lymphoma (LCAL) was coined. When one year later Kadin et al. [32] proposed the alternative immunohistological term Ki-1 lymphoma, it was popular among clinicians but strongly disliked by pathologists. Thus, the phenotypic feature of Ki-1 immunoreactivity is, on the one hand, not specific for LCAL, being also found in many other subtypes of lymphoma of B-cell and T-cell lineage and even in non-lymphoid tumours, i.e. embryonal carcinoma; on the other hand, Ki-1 is not invariably exhibited in LCAL, leading to nonsense casuistics of “Ki-1 negative Ki-1 lymphoma”. However, the morphologically based terminology also became problematic, when Kinney et al [33] described a small-cell-predominant variant of primary Ki-1 (CD30)+ T-cell lymphoma, resulting in a semantically paradoxical “large cell anaplastic lymphoma, small cell variant”.

When the ILSG proclaimed the REAL classification, the term anaplastic large cell lymphoma (ALCL) was restricted to T-cell and null-cell neoplasms, both of which, irrespective of different antigenic profiles concerning the expression of T-cell markers, showed clonally rearranged T-cell receptor genes of γ or β type in about 90% of cases. However, in contrast to the Kiell classification, anaplastic tumours of B-cell phenotype were separated and put into the diffuse large B-cell lymphoma group (see above). In the range of a morphological spectrum, classical ALCL was distinguished from a small cell variant and a lymphoblastic variant, whereas ALCL Hodgkin’s-like [34], as an entity, remained provisional. Clinically, the REAL classification distinguished between two distinct forms of primary ALCL: a systemic form involving lymph nodes and extranodal sites and a primary cutaneous form, the second of which remained provisional, showing a considerable clinical, morphological, phenotypic, and genotypic overlap with type-A lymphomatoid papulosis [35]. However, primary cutaneous forms were distinct from systemic forms: phenotypically by immunoreactivity with the cutaneous lymphocyte antigen (CLA, HECA-452) and negativity for EMA, and genotypically by the absence of t(2;5) translocation.

In the WHO classification ALCL, a tumour originating from activated mature cytotoxic T-cells, is defined as a neoplasm composed of large pleomorphic cells often with horseshoe- or kidney-shaped nuclei (so called hallmark cells) with abundant cytoplasm, strong CD30 expression on the cell membrane or the Golgi region in the great majority of tumour cells, and no expression of B-cell antigens [36]. The WHO classification distinguishes three subtypes of ALCL: (1) systemic ALCL, ALK+, typically presenting as advanced stage disease in young men, highly sensitive to chemotherapy and with a favourable prognosis (5-year (y) overall survival (os): 80%; 10-y os: 70–90%); (2) systemic ALCL, ALK+, affecting older patients, located less often at extranodal sites and with a markedly less favourable prognosis (5-y os: 40%); and (3) cutaneous ALCL, by definition a localised disease in the skin over 6 months [18], highly sensitive to local treatment and with an excellent prognosis (10-y os: >90%). Since cutaneous ALCL may represent a continuous spectrum with type A lymphomatoid papulosis, both of these conditions are subsumed in the WHO classification under the term primary cutaneous CD30-positive T-cell lymphoproliferative disorders. Morphologically, lymphoblastic, small cell, giant cell rich, signet ring cell-like, sarcomatoid, neutrophilic, and eosinophilic variants are distinguished from ALCL, common type, whereas ALCL Hodgkin’s-like, recognised as a provisional entity in the REAL classification, no longer figures in the WHO classification. Thus, most such cases could be identified phenotypically as Hodgkin lymphomas characterised by expression of CD15, LMP-EBV, and, in part, of B-cell markers, while phenotypic profiles, such as CD30+/CD15−, LMP-EBV+, EMA+, CD45+, CD3+/−, CD4+/−, CD8+, CD2−, CD43−, TIA-1−, Granzyme B+, Perforin+, Clusterin+, ALK+/−, CD56−/−, CD20+, CD79a+, and BSAP-characterise ALCL, leaving out a few cases only of so-called grey zone lymphoma. However, the molecular hallmark features found in the majority of systemic ALCL cases, but not in primary cutaneous forms, are genetic alterations of the anaplastic lymphoma kinase (ALK) locus on chromosome 2. In 70–80% of cases, the t(2;5) translocation juxtaposes parts of the nucleophosmin (NPM) gene (5q35) to the ALK gene (2p23), bringing the ALK gene under the control of the NPM promoter. The formation of this NPM-ALK hybrid gene results in continuous activation of the NPM-ALK fusion transcript and overexpression of the chimeric NPM-ALK protein (p80). Alternative genetic aberrations, such as t(1;12), t(2;3), Inv2, and t(2;17) are less often found, resulting in the formation of variant TPM3-ALK (tropomyosin 3), TFG-ALK (Trk-fusion gene), ATIC-ALK (pur-H gene), and CLTC-ALK (clathrin heavy chain) hybrid genes, fusion transcripts and chimeric proteins respectively [36]. However,
variable genetic alterations of the ALK locus and heterogeneous phenotypic ALK profiles may fi-

nally cast doubt on whether ALCL is ultimately the correct term.

Hodgkin lymphomas

Lymphocyte-rich classical Hodgkin lymphoma

In the WHO classification Hodgkin’s disease, as a term, is replaced by Hodgkin lymphoma. The lymphocyte-rich subtype of classical Hodgkin lymphoma, as recognised in the REAL classification, is no longer provisional but a disease entity corresponding in its nodular form to follicular Hodgkin’s disease as first described by Ashton-Key et al. [37]. However, lymphocyte-rich classical Hodgkin lymphoma needs to be clearly distinguished from nodular lymphocyte predominant Hodgkin lymphoma, which is identical to nodular paragranuloma in the REAL classification.

References


Correspondence:
Sergio B Cogliatti, MD
Chairman of the SAKK Pathology Reference Centre for Malignant Lymphomas
Department of Pathology
Cantonal Hospital St. Gallen
Rorschacherstrasse 95
CH-9007 St.Gallen
E-Mail: sergio.cogliatti@kssg.ch
We thank Professor Robert Maurer for his helpful comments and for kindly reviewing the manuscript.


The many reasons why you should choose SMW to publish your research

What Swiss Medical Weekly has to offer:

- SMW’s impact factor has been steadily rising, to the current 1.537
- Open access to the publication via the Internet, therefore wide audience and impact
- Rapid listing in Medline
- LinkOut-button from PubMed with link to the full text website http://www.smw.ch (direct link from each SMW record in PubMed)
- No-nonsense submission – you submit a single copy of your manuscript by e-mail attachment
- Peer review based on a broad spectrum of international academic referees
- Assistance of our professional statistician for every article with statistical analyses
- Fast peer review, by e-mail exchange with the referees
- Prompt decisions based on weekly conferences of the Editorial Board
- Prompt notification on the status of your manuscript by e-mail
- Professional English copy editing
- No page charges and attractive colour offprints at no extra cost

Editorial Board
Prof. Jean-Michel Dayer, Geneva
Prof. Peter Gehr, Berne
Prof. André P. Perruchoud, Basel
Prof. Andreas Schaffner, Zurich
(Editor in chief)
Prof. Werner Straub, Berne
Prof. Ludwig von Segesser, Lausanne

International Advisory Committee
Prof. K. E. Juhani Airaksinen, Turku, Finland
Prof. Anthony Bayes de Luna, Barcelona, Spain
Prof. Hubert E. Blum, Freiburg, Germany
Prof. Walter E. Haefeli, Heidelberg, Germany
Prof. Nino Kuenzli, Los Angeles, USA
Prof. René Lutter, Amsterdam, The Netherlands
Prof. Claude Martin, Marseille, France
Prof. Josef Patsch, Innsbruck, Austria
Prof. Luigi Tavazzi, Pavia, Italy

We evaluate manuscripts of broad clinical interest from all specialities, including experimental medicine and clinical investigation.

We look forward to receiving your paper!

Guidelines for authors:
http://www.smw.ch/set_authors.html

Impact factor Swiss Medical Weekly

All manuscripts should be sent in electronic form, to:

EMH Swiss Medical Publishers Ltd.
SMW Editorial Secretariat
Farnburgerstrasse 8
CH-4132 Muttenz

Manuscripts: submission@smw.ch
Letters to the editor: letters@smw.ch
Editorial Board: red@smw.ch
Internet: http://www.smw.ch